CA2395117C - Cellules du type spore et leurs applications - Google Patents

Cellules du type spore et leurs applications Download PDF

Info

Publication number: CA2395117C
Authority: CA; Canada
Prior art keywords: cell; spore; cells; tissue; isolated
Prior art date: 1999-12-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2395117A

Other languages

English (en)

Other versions

CA2395117A1 (fr

Inventor

Charles A. Vacanti

Martin P. Vacanti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vcell Therapeutics Inc

Original Assignee

VBI Technologies LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-30

Filing date

2000-12-29

Publication date

2016-03-22

2000-12-29 Application filed by VBI Technologies LLC filed Critical VBI Technologies LLC

2000-12-29 Priority to CA2917517A priority Critical patent/CA2917517A1/fr

2001-07-12 Publication of CA2395117A1 publication Critical patent/CA2395117A1/fr

2016-03-22 Application granted granted Critical

2016-03-22 Publication of CA2395117C publication Critical patent/CA2395117C/fr

2020-12-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 claims description 746
210000001519 tissue Anatomy 0.000 claims description 195
239000000017 hydrogel Substances 0.000 claims description 82
238000000034 method Methods 0.000 claims description 79
239000000203 mixture Substances 0.000 claims description 66
210000003491 skin Anatomy 0.000 claims description 58
241001465754 Metazoa Species 0.000 claims description 47
239000000523 sample Substances 0.000 claims description 41
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 38
206010028980 Neoplasm Diseases 0.000 claims description 27
210000004185 liver Anatomy 0.000 claims description 27
210000004072 lung Anatomy 0.000 claims description 27
201000011510 cancer Diseases 0.000 claims description 20
102000004877 Insulin Human genes 0.000 claims description 19
108090001061 Insulin Proteins 0.000 claims description 19
229940125396 insulin Drugs 0.000 claims description 19
238000012258 culturing Methods 0.000 claims description 18
210000001525 retina Anatomy 0.000 claims description 18
241000124008 Mammalia Species 0.000 claims description 17
229910052760 oxygen Inorganic materials 0.000 claims description 16
239000001301 oxygen Substances 0.000 claims description 16
210000000496 pancreas Anatomy 0.000 claims description 16
102000008730 Nestin Human genes 0.000 claims description 15
108010088225 Nestin Proteins 0.000 claims description 15
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
208000027418 Wounds and injury Diseases 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 14
239000008280 blood Substances 0.000 claims description 14
102000004142 Trypsin Human genes 0.000 claims description 13
108090000631 Trypsin Proteins 0.000 claims description 13
239000012588 trypsin Substances 0.000 claims description 13
210000004207 dermis Anatomy 0.000 claims description 12
210000002615 epidermis Anatomy 0.000 claims description 12
210000003734 kidney Anatomy 0.000 claims description 12
210000005055 nestin Anatomy 0.000 claims description 12
238000004627 transmission electron microscopy Methods 0.000 claims description 11
230000002500 effect on skin Effects 0.000 claims description 10
210000000411 amacrine cell Anatomy 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 9
206010012601 diabetes mellitus Diseases 0.000 claims description 8
239000012528 membrane Substances 0.000 claims description 7
208000003098 Ganglion Cysts Diseases 0.000 claims description 6
208000005400 Synovial Cyst Diseases 0.000 claims description 6
210000004100 adrenal gland Anatomy 0.000 claims description 6
210000002510 keratinocyte Anatomy 0.000 claims description 6
102000029816 Collagenase Human genes 0.000 claims description 5
108060005980 Collagenase Proteins 0.000 claims description 5
229960002424 collagenase Drugs 0.000 claims description 5
210000002216 heart Anatomy 0.000 claims description 5
210000002287 horizontal cell Anatomy 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
210000002752 melanocyte Anatomy 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
210000001127 pigmented epithelial cell Anatomy 0.000 claims description 5
210000001732 sebaceous gland Anatomy 0.000 claims description 5
239000004094 surface-active agent Substances 0.000 claims description 5
210000000106 sweat gland Anatomy 0.000 claims description 5
239000012472 biological sample Substances 0.000 claims description 4
230000002950 deficient Effects 0.000 claims description 4
210000000936 intestine Anatomy 0.000 claims description 4
210000000716 merkel cell Anatomy 0.000 claims description 4
210000000633 nuclear envelope Anatomy 0.000 claims description 4
210000003932 urinary bladder Anatomy 0.000 claims description 4
241000271566 Aves Species 0.000 claims description 3
102000005157 Somatostatin Human genes 0.000 claims description 3
108010056088 Somatostatin Proteins 0.000 claims description 3
102000038379 digestive enzymes Human genes 0.000 claims description 3
108091007734 digestive enzymes Proteins 0.000 claims description 3
210000003981 ectoderm Anatomy 0.000 claims description 3
210000001900 endoderm Anatomy 0.000 claims description 3
210000003780 hair follicle Anatomy 0.000 claims description 3
210000003716 mesoderm Anatomy 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
102400000321 Glucagon Human genes 0.000 claims description 2
108060003199 Glucagon Proteins 0.000 claims description 2
102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
229960004666 glucagon Drugs 0.000 claims description 2
238000003365 immunocytochemistry Methods 0.000 claims description 2
210000005034 parasympathetic neuron Anatomy 0.000 claims description 2
210000000608 photoreceptor cell Anatomy 0.000 claims description 2
230000002889 sympathetic effect Effects 0.000 claims description 2
208000019693 Lung disease Diseases 0.000 claims 3
206010072170 Skin wound Diseases 0.000 claims 3
208000019423 liver disease Diseases 0.000 claims 3
208000015122 neurodegenerative disease Diseases 0.000 claims 3
210000001124 body fluid Anatomy 0.000 abstract description 10
229920000642 polymer Polymers 0.000 description 37
210000000130 stem cell Anatomy 0.000 description 30
241000700159 Rattus Species 0.000 description 27
-1 lipid compounds Chemical class 0.000 description 21
239000007788 liquid Substances 0.000 description 21
230000004069 differentiation Effects 0.000 description 19
239000000243 solution Substances 0.000 description 19
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 17
239000000499 gel Substances 0.000 description 15
239000003102 growth factor Substances 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
229940088597 hormone Drugs 0.000 description 12
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 11
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
239000005556 hormone Substances 0.000 description 11
210000000056 organ Anatomy 0.000 description 11
239000000047 product Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
239000000835 fiber Substances 0.000 description 10
239000000463 material Substances 0.000 description 10
239000007787 solid Substances 0.000 description 10
206010052428 Wound Diseases 0.000 description 9
150000001768 cations Chemical class 0.000 description 9
230000006870 function Effects 0.000 description 9
235000015097 nutrients Nutrition 0.000 description 9
239000000725 suspension Substances 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
235000010443 alginic acid Nutrition 0.000 description 8
229920000615 alginic acid Polymers 0.000 description 8
230000036760 body temperature Effects 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
210000003494 hepatocyte Anatomy 0.000 description 8
239000002609 medium Substances 0.000 description 8
239000011148 porous material Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000008439 repair process Effects 0.000 description 8
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
230000002378 acidificating effect Effects 0.000 description 7
230000006378 damage Effects 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
210000003195 fascia Anatomy 0.000 description 7
238000002513 implantation Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
239000011824 nuclear material Substances 0.000 description 7
229920000747 poly(lactic acid) Polymers 0.000 description 7
239000004626 polylactic acid Substances 0.000 description 7
238000001665 trituration Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
229930186217 Glycolipid Natural products 0.000 description 6
102000014736 Notch Human genes 0.000 description 6
108010070047 Notch Receptors Proteins 0.000 description 6
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 6
239000003242 anti bacterial agent Substances 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 6
239000002775 capsule Substances 0.000 description 6
229920001577 copolymer Polymers 0.000 description 6
238000004132 cross linking Methods 0.000 description 6
230000007717 exclusion Effects 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
208000014674 injury Diseases 0.000 description 6
238000002955 isolation Methods 0.000 description 6
239000008188 pellet Substances 0.000 description 6
229920002627 poly(phosphazenes) Polymers 0.000 description 6
229920005594 polymer fiber Polymers 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000186 progesterone Substances 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
230000002207 retinal effect Effects 0.000 description 6
229910052711 selenium Inorganic materials 0.000 description 6
239000011669 selenium Substances 0.000 description 6
210000000278 spinal cord Anatomy 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
102000008186 Collagen Human genes 0.000 description 5
108010035532 Collagen Proteins 0.000 description 5
102000004338 Transferrin Human genes 0.000 description 5
108090000901 Transferrin Proteins 0.000 description 5
229940072056 alginate Drugs 0.000 description 5
150000001450 anions Chemical class 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
230000024245 cell differentiation Effects 0.000 description 5
238000002659 cell therapy Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229920001436 collagen Polymers 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
239000012634 fragment Substances 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
210000004153 islets of langerhan Anatomy 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
210000001164 retinal progenitor cell Anatomy 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
239000012581 transferrin Substances 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
241001494479 Pecora Species 0.000 description 4
241000282887 Suidae Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000012620 biological material Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000001493 electron microscopy Methods 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
230000012010 growth Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000000717 retained effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000010186 staining Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000007704 transition Effects 0.000 description 4
239000002699 waste material Substances 0.000 description 4
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical group [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920002683 Glycosaminoglycan Polymers 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
206010038848 Retinal detachment Diseases 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
102000005840 alpha-Galactosidase Human genes 0.000 description 3
108010030291 alpha-Galactosidase Proteins 0.000 description 3
210000002453 autonomic neuron Anatomy 0.000 description 3
229920001400 block copolymer Polymers 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
229910001424 calcium ion Inorganic materials 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
210000000845 cartilage Anatomy 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000007387 excisional biopsy Methods 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
238000000386 microscopy Methods 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
125000004437 phosphorous atom Chemical group 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000004264 retinal detachment Effects 0.000 description 3
238000001878 scanning electron micrograph Methods 0.000 description 3
230000011664 signaling Effects 0.000 description 3
241000894007 species Species 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000000153 supplemental effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
208000019838 Blood disease Diseases 0.000 description 2
102000011045 Chloride Channels Human genes 0.000 description 2
108010062745 Chloride Channels Proteins 0.000 description 2
229920001287 Chondroitin sulfate Polymers 0.000 description 2
241000283070 Equus zebra Species 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
230000001919 adrenal effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000000941 bile Anatomy 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
229940088623 biologically active substance Drugs 0.000 description 2
210000003443 bladder cell Anatomy 0.000 description 2
231100001015 blood dyscrasias Toxicity 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
230000001680 brushing effect Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002153 concerted effect Effects 0.000 description 2
230000002338 cryopreservative effect Effects 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
210000001339 epidermal cell Anatomy 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
208000018706 hematopoietic system disease Diseases 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
210000004923 pancreatic tissue Anatomy 0.000 description 2
238000002135 phase contrast microscopy Methods 0.000 description 2
108091008695 photoreceptors Proteins 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
230000000063 preceeding effect Effects 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
238000009256 replacement therapy Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
210000001957 retinal vein Anatomy 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000007790 scraping Methods 0.000 description 2
239000008279 sol Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
125000000542 sulfonic acid group Chemical group 0.000 description 2
210000000225 synapse Anatomy 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
230000008733 trauma Effects 0.000 description 2
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000035899 viability Effects 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
241000242757 Anthozoa Species 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
206010063601 Exposure to extreme temperature Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
208000024720 Fabry Disease Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920000153 Povidone-iodine Polymers 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
102000011842 Serrate-Jagged Proteins Human genes 0.000 description 1
108010036039 Serrate-Jagged Proteins Proteins 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
208000028990 Skin injury Diseases 0.000 description 1
206010040893 Skin necrosis Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
238000003917 TEM image Methods 0.000 description 1
102400001320 Transforming growth factor alpha Human genes 0.000 description 1
101800004564 Transforming growth factor alpha Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013528 artificial neural network Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
229920013641 bioerodible polymer Polymers 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
238000005266 casting Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
208000022371 chronic pain syndrome Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000000748 compression moulding Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000010949 copper Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000011557 critical solution Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000001804 debridement Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000032459 dedifferentiation Effects 0.000 description 1
238000002716 delivery method Methods 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229940111205 diastase Drugs 0.000 description 1
239000012973 diazabicyclooctane Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
208000002296 eclampsia Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
238000000635 electron micrograph Methods 0.000 description 1
238000010218 electron microscopic analysis Methods 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000012407 engineering method Methods 0.000 description 1
230000007159 enucleation Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012526 feed medium Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001879 gelation Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000030214 innervation Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000002879 macerating effect Effects 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000037306 mature skin Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000002780 melanosome Anatomy 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
206010028093 mucopolysaccharidosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
210000004224 pleura Anatomy 0.000 description 1
229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
229920001482 poly(N-isopropylacrylamide) copolymer Polymers 0.000 description 1
229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
239000002745 poly(ortho ester) Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
229960001621 povidone-iodine Drugs 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000001927 retinal artery Anatomy 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000004621 scanning probe microscopy Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
210000004003 subcutaneous fat Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229920001187 thermosetting polymer Polymers 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000008354 tissue degradation Effects 0.000 description 1
230000025366 tissue development Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA2395117A 1999-12-30 2000-12-29 Cellules du type spore et leurs applications Expired - Fee Related CA2395117C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2917517A CA2917517A1 (fr)	1999-12-30	2000-12-29	Cellules du type spore et leurs applications

Applications Claiming Priority (11)

Application Number	Priority Date	Filing Date	Title
US47561199A	1999-12-30	1999-12-30
US47639499A	1999-12-30	1999-12-30
US47604799A	1999-12-30	1999-12-30
US47536999A	1999-12-30	1999-12-30
US09/475,611		1999-12-30
US09/476,047		1999-12-30
US09/475,369		1999-12-30
US09/476,394		1999-12-30
US24434700P	2000-10-30	2000-10-30
US60/244,347		2000-10-30
PCT/US2000/035606 WO2001049113A1 (fr)	1999-12-30	2000-12-29	Cellules du type spore et leurs applications

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2917517A Division CA2917517A1 (fr)	1999-12-30	2000-12-29	Cellules du type spore et leurs applications

Publications (2)

Publication Number	Publication Date
CA2395117A1 CA2395117A1 (fr)	2001-07-12
CA2395117C true CA2395117C (fr)	2016-03-22

Family

ID=27540195

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2395117A Expired - Fee Related CA2395117C (fr)	1999-12-30	2000-12-29	Cellules du type spore et leurs applications

Country Status (4)

Country	Link
EP (1)	EP1241939A1 (fr)
AU (1)	AU2295201A (fr)
CA (1)	CA2395117C (fr)
WO (1)	WO2001049113A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458589B1 (en) *	2000-04-27	2002-10-01	Geron Corporation	Hepatocyte lineage cells derived from pluripotent stem cells
US7473555B2 (en)	2000-04-27	2009-01-06	Geron Corporation	Protocols for making hepatocytes from embryonic stem cells
US7256042B2 (en)	2000-04-27	2007-08-14	Geron Corporation	Process for making hepatocytes from pluripotent stem cells
US7282366B2 (en)	2000-04-27	2007-10-16	Geron Corporation	Hepatocytes for therapy and drug screening made from embryonic stem cells
US20040247575A1 (en)	2003-06-03	2004-12-09	Caplice Noel M.	Smooth muscle progenitor cells
US8043614B2 (en)	2004-03-09	2011-10-25	Ahlfors Jan-Eric W	Autogenic living scaffolds and living tissue matrices: methods and uses thereof
DK1948259T3 (en)	2005-10-26	2017-04-10	Genesis Tech Ltd	ACELLULAR BIOabsorbable Tissue Regeneration Matrices Produced by Incubation of ACELLULAR BLOOD PRODUCTS
US8148151B2 (en)	2006-06-02	2012-04-03	Geron Corporation	Differentiation of primate pluripotent cells to hepatocyte-lineage cells
JP2013510577A (ja) *	2009-11-12	2013-03-28	ブイビーアイテクノロジーズ，エルエルシー	胞子様細胞の亜集団およびその用途

2000
- 2000-12-29 WO PCT/US2000/035606 patent/WO2001049113A1/fr not_active Ceased
- 2000-12-29 AU AU22952/01A patent/AU2295201A/en not_active Abandoned
- 2000-12-29 EP EP00986772A patent/EP1241939A1/fr not_active Withdrawn
- 2000-12-29 CA CA2395117A patent/CA2395117C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2395117A1 (fr)	2001-07-12
WO2001049113A1 (fr)	2001-07-12
AU2295201A (en)	2001-07-16
EP1241939A1 (fr)	2002-09-25

Legal Events

Date	Code	Title	Description
2005-12-14	EEER	Examination request
2020-02-10	MKLA	Lapsed	Effective date: 20191230

Publication	Publication Date	Title
US7964394B2 (en)	2011-06-21	Spore-like cells and uses thereof
US7319035B2 (en)	2008-01-15	Biological scaffolding material
EP1076533B1 (fr)	2007-04-11	Developpement et support guides de compositions de cellules et d'hydrogel
US7601525B2 (en)	2009-10-13	Alginate gel scaffold having a plurality of continuous parallel microtubular copper capillaries
US7060492B2 (en)	2006-06-13	Isolation of spore-like cells from tissues exposed to extreme conditions
US20100310627A1 (en)	2010-12-09	Xenotransplant for Stroke Therapy
JPH04501657A (ja)	1992-03-26	細胞および組織の三次元培養系
US8709081B2 (en)	2014-04-29	Cellular scaffold
US20070286880A1 (en)	2007-12-13	Inoculated spongiform scaffold for transplantation and tissue regeneration
US7560275B2 (en)	2009-07-14	Compositions and methods for generating skin
CA2395117C (fr)	2016-03-22	Cellules du type spore et leurs applications
KR102081356B1 (ko)	2020-02-25	포자를 닮은 세포들의 계군 및 그 용도
KR20200082352A (ko)	2020-07-08	타액선 유래 줄기세포를 타액선 조직으로 분화시키는 방법 및 구강 건조증 치료 또는 예방용 조성물
CA2917517A1 (fr)	2001-07-12	Cellules du type spore et leurs applications
KR102332926B1 (ko)	2021-11-30	코중격 연골세포를 포함하는 연골손상 치료용 약학적 조성물
Aurand	2014	The characterization of hyaluronic acid and polyethylene glycol hydrogels for neural tissue engineering
Ko et al.	2018	Tissue engineering of the urogenital system
Finch	2018	Delivering nanoengineered neural stem cells within neurosurgical grade biomaterials
Zhang	2004	The adult brain tissue response to hollow fiber membranes of varying surface architecture with or without cotransplanted cells
Stocum	1998	Regenerative Biology: New Tissues For Old
IL91536A (en)	1996-10-31	Three-dimensional cell and tissue culture system comprising parenchymal cells cultured on a living stromal tissue methods for preparing said culturing system and uses thereof